PKM and Alzheimer disease: CBD, for example, acts on various receptors as well as enzymes, transporters, and ion channels.[3] Furthermore, the CBD‐derivative CIAC001, which showed improved anti‐neuroinflammatory properties, was found to act on pyruvate kinase M2 (PKM2) as analyzed by affinity‐based protein profiling (AfBPP).[4] Both phytocannabinoids, THC and CBD, show great potential in the treatment of Alzheimer's disease (AD).[5] But especially since THC shows strong activity on CB1R and CB2R, its potential clinical application is limited due to its psychoactive side effects.